QSAR-derived affinity fingerprints (part 2): modeling performance for potency prediction
暂无分享,去创建一个
Daniel Svozil | Andreas Bender | Isidro Cortés-Ciriano | Ctibor Škuta | A. Bender | I. Cortés-Ciriano | D. Svozil | C. Škuta
[1] Andreas Bender,et al. Neighbours of cancer-related proteins have key influence on pathogenesis and could increase the drug target space for anticancer therapies , 2017, npj Systems Biology and Applications.
[2] Eric J. Martin,et al. Profile-QSAR: A Novel meta-QSAR Method that Combines Activities across the Kinase Family To Accurately Predict Affinity, Selectivity, and Cellular Activity , 2011, J. Chem. Inf. Model..
[3] Robert P. Sheridan,et al. Three Useful Dimensions for Domain Applicability in QSAR Models Using Random Forest , 2012, J. Chem. Inf. Model..
[4] N. Cox,et al. Clinical drug response can be predicted using baseline gene expression levels and in vitro drug sensitivity in cell lines , 2014, Genome Biology.
[5] Hilde van der Togt,et al. Publisher's Note , 2003, J. Netw. Comput. Appl..
[6] R. Shoemaker. The NCI60 human tumour cell line anticancer drug screen , 2006, Nature Reviews Cancer.
[7] Benjamin Haibe-Kains,et al. Inconsistency in large pharmacogenomic studies , 2013, Nature.
[8] Julio Saez-Rodriguez,et al. Looking beyond the cancer cell for effective drug combinations , 2016, Genome Medicine.
[9] N. Curtin. PARP inhibitors for anticancer therapy. , 2014, Biochemical Society transactions.
[10] Kian Behbakht,et al. PARP inhibitors: Clinical utility and possibilities of overcoming resistance. , 2017, Gynecologic oncology.
[11] Adam A. Margolin,et al. The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.
[12] J. Mason. Use of Biological Fingerprints Versus Structure/Chemotypes to Describe Molecules , 2010 .
[13] Scott D. Kahn,et al. Current Status of Methods for Defining the Applicability Domain of (Quantitative) Structure-Activity Relationships , 2005, Alternatives to laboratory animals : ATLA.
[14] Andreas Bender,et al. In Silico Target Predictions: Defining a Benchmarking Data Set and Comparison of Performance of the Multiclass Naïve Bayes and Parzen-Rosenblatt Window , 2013, J. Chem. Inf. Model..
[15] A. Bruna,et al. Machine learning models to predict in vivo drug response via optimal dimensionality reduction of tumour molecular profiles , 2018, bioRxiv.
[16] Michael J. Keiser,et al. Large Scale Prediction and Testing of Drug Activity on Side-Effect Targets , 2012, Nature.
[17] Roberto Todeschini,et al. Handbook of Molecular Descriptors , 2002 .
[18] Isidro Cortes-Ciriano,et al. Deep Confidence: A Computationally Efficient Framework for Calculating Reliable Errors for Deep Neural Networks , 2018, Journal of chemical information and modeling.
[19] Phelim Bradley,et al. Corrigendum: Rapid antibiotic-resistance predictions from genome sequence data for Staphylococcus aureus and Mycobacterium tuberculosis , 2016, Nature Communications.
[20] Isidro Cortes-Ciriano,et al. Reliable Prediction Errors for Deep Neural Networks Using Test-Time Dropout , 2019, J. Chem. Inf. Model..
[21] D. Svozil,et al. QSAR-derived affinity fingerprints (part 1): fingerprint construction and modeling performance for similarity searching, bioactivity classification and scaffold hopping , 2020, Journal of Cheminformatics.
[22] Ruili Huang,et al. Modelling the Tox21 10 K chemical profiles for in vivo toxicity prediction and mechanism characterization , 2016, Nature Communications.
[23] Alexander Tropsha,et al. Trust, But Verify: On the Importance of Chemical Structure Curation in Cheminformatics and QSAR Modeling Research , 2010, J. Chem. Inf. Model..
[24] Isidro Cortes-Ciriano,et al. Improved large-scale prediction of growth inhibition patterns using the NCI60 cancer cell line panel , 2015, Bioinform..
[25] Robert P. Sheridan,et al. Using Random Forest To Model the Domain Applicability of Another Random Forest Model , 2013, J. Chem. Inf. Model..
[26] Michael P. Morrissey,et al. Pharmacogenomic agreement between two cancer cell line data sets , 2015, Nature.
[27] Nci Dream Community. A community effort to assess and improve drug sensitivity prediction algorithms , 2014 .
[28] Anatoly G Artemenko,et al. Interpretation of QSAR Models Based on Random Forest Methods , 2011, Molecular informatics.
[29] Gerta Rücker,et al. y-Randomization and Its Variants in QSPR/QSAR , 2007, J. Chem. Inf. Model..
[30] P. Sorger,et al. Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs , 2016, Nature Methods.
[31] Gergely Zahoránszky-Köhalmi,et al. Drug Effect Prediction by Polypharmacology-Based Interaction Profiling , 2012, J. Chem. Inf. Model..
[32] Isidro Cortes-Ciriano,et al. Comparing the Influence of Simulated Experimental Errors on 12 Machine Learning Algorithms in Bioactivity Modeling Using 12 Diverse Data Sets , 2015, J. Chem. Inf. Model..
[33] U. Lessel,et al. In vitro and in silico affinity fingerprints: Finding similarities beyond structural classes , 2000 .
[34] Isidro Cortes-Ciriano,et al. Polypharmacology modelling using proteochemometrics (PCM): recent methodological developments, applications to target families, and future prospects , 2015 .
[35] Csaba Hetényi,et al. Contribution of 2D and 3D Structural Features of Drug Molecules in the Prediction of Drug Profile Matching , 2012, J. Chem. Inf. Model..
[36] Karsten M. Borgwardt,et al. Prediction of human population responses to toxic compounds by a collaborative competition , 2015, Nature Biotechnology.
[37] G. Konecny,et al. PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions , 2016, British Journal of Cancer.
[38] Isidro Cortés-Ciriano,et al. Detecting the mutational signature of homologous recombination deficiency in clinical samples , 2019, Nature Genetics.
[39] Robert L. Mason,et al. Statistical Principles in Experimental Design , 2003 .
[40] Benito Munoz,et al. Identification of cancer cytotoxic modulators of PDE3A by predictive chemogenomics , 2015, Nature chemical biology.
[41] Andreas Bender,et al. How Similar Are Similarity Searching Methods? A Principal Component Analysis of Molecular Descriptor Space , 2009, J. Chem. Inf. Model..
[42] Roger A. Sayle,et al. Comparing structural fingerprints using a literature-based similarity benchmark , 2016, Journal of Cheminformatics.
[43] Julio Saez-Rodriguez,et al. Machine Learning Prediction of Cancer Cell Sensitivity to Drugs Based on Genomic and Chemical Properties , 2012, PloS one.
[44] George Papadatos,et al. ChEMBL web services: streamlining access to drug discovery data and utilities , 2015, Nucleic Acids Res..
[45] Scott Boyer,et al. Introducing Conformal Prediction in Predictive Modeling. A Transparent and Flexible Alternative to Applicability Domain Determination , 2014, J. Chem. Inf. Model..
[46] Xiang-Wei Zhu,et al. All-Assay-Max2 pQSAR: Activity predictions as accurate as 4-concentration IC50s for 8,558 Novartis assays , 2019 .
[47] V. Poroikov,et al. PASS: identification of probable targets and mechanisms of toxicity , 2007, SAR and QSAR in environmental research.
[48] Jürgen Bajorath,et al. Exploring activity cliffs in medicinal chemistry. , 2012, Journal of medicinal chemistry.
[49] J. Dearden,et al. QSAR modeling: where have you been? Where are you going to? , 2014, Journal of medicinal chemistry.
[50] Hans Briem,et al. Flexsim-X: A Method for the Detection of Molecules with Similar Biological Activity , 2000, J. Chem. Inf. Comput. Sci..
[51] Andreas Bender,et al. "Bayes Affinity Fingerprints" Improve Retrieval Rates in Virtual Screening and Define Orthogonal Bioactivity Space: When Are Multitarget Drugs a Feasible Concept? , 2006, J. Chem. Inf. Model..
[52] B. J. Winer. Statistical Principles in Experimental Design , 1992 .
[53] Eric J. Martin,et al. Profile-QSAR 2.0: Kinase Virtual Screening Accuracy Comparable to Four-Concentration IC50s for Realistically Novel Compounds , 2017, J. Chem. Inf. Model..
[54] Pedro J. Ballester,et al. Predicting Synergism of Cancer Drug Combinations Using NCI-ALMANAC Data , 2018, bioRxiv.
[55] George Papadatos,et al. Want Drugs? Use Python , 2016, ArXiv.
[56] M. Toulmonde,et al. A review of PARP inhibitors: from bench to bedside. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[57] David Rogers,et al. Extended-Connectivity Fingerprints , 2010, J. Chem. Inf. Model..
[58] Gaël Varoquaux,et al. Scikit-learn: Machine Learning in Python , 2011, J. Mach. Learn. Res..
[59] M. Taron,et al. Pharmacogenomic biomarkers for personalized cancer treatment , 2015, Journal of internal medicine.
[60] Laura M. Heiser,et al. A community effort to assess and improve drug sensitivity prediction algorithms , 2014, Nature Biotechnology.
[61] Amir K. Foroushani,et al. Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen , 2019, Nature Communications.
[62] David M. Rocke,et al. Predicting ligand binding to proteins by affinity fingerprinting. , 1995, Chemistry & biology.
[63] Meir Glick,et al. Prediction of Biological Targets for Compounds Using Multiple-Category Bayesian Models Trained on Chemogenomics Databases , 2006, J. Chem. Inf. Model..
[64] John P. Overington,et al. ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..
[65] Andreas Bender,et al. How Consistent are Publicly Reported Cytotoxicity Data? Large‐Scale Statistical Analysis of the Concordance of Public Independent Cytotoxicity Measurements , 2016, ChemMedChem.
[66] Sven Kosub,et al. A note on the triangle inequality for the Jaccard distance , 2016, Pattern Recognit. Lett..
[67] Marvin Johnson,et al. Concepts and applications of molecular similarity , 1990 .
[68] Isidro Cortes-Ciriano,et al. Improved Chemical Structure-Activity Modeling Through Data Augmentation , 2015, J. Chem. Inf. Model..
[69] Mohammad Fallahi-Sichani,et al. Metrics other than potency reveal systematic variation in responses to cancer drugs. , 2013, Nature chemical biology.
[70] Kunal Roy,et al. Selected Statistical Methods in QSAR , 2015 .
[71] Robert D Clark,et al. Neighborhood behavior: a useful concept for validation of "molecular diversity" descriptors. , 1996, Journal of medicinal chemistry.
[72] Eric Jones,et al. SciPy: Open Source Scientific Tools for Python , 2001 .
[73] Péter Hári,et al. Virtual Affinity Fingerprints for Target Fishing: A New Application of Drug Profile Matching , 2013, J. Chem. Inf. Model..
[74] CHUN WEI YAP,et al. PaDEL‐descriptor: An open source software to calculate molecular descriptors and fingerprints , 2011, J. Comput. Chem..
[75] R. Glen,et al. Molecular similarity: a key technique in molecular informatics. , 2004, Organic & biomolecular chemistry.
[76] A. Fliri,et al. Biological spectra analysis: Linking biological activity profiles to molecular structure. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[77] Peter S. Kutchukian,et al. Rethinking molecular similarity: comparing compounds on the basis of biological activity. , 2012, ACS chemical biology.
[78] Andreas Bender,et al. Modelling of compound combination effects and applications to efficacy and toxicity: state-of-the-art, challenges and perspectives. , 2016, Drug discovery today.
[79] Andreas Bender,et al. KekuleScope: prediction of cancer cell line sensitivity and compound potency using convolutional neural networks trained on compound images , 2018, Journal of Cheminformatics.
[80] Yanli Wang,et al. Identifying Compound-Target Associations by Combining Bioactivity Profile Similarity Search and Public Databases Mining , 2011, J. Chem. Inf. Model..
[81] S. Ramaswamy,et al. Systematic identification of genomic markers of drug sensitivity in cancer cells , 2012, Nature.
[82] Benjamin Haibe-Kains,et al. Revisiting inconsistency in large pharmacogenomic studies , 2015, bioRxiv.
[83] Andreas Bender,et al. How Diverse Are Diversity Assessment Methods? A Comparative Analysis and Benchmarking of Molecular Descriptor Space , 2014, J. Chem. Inf. Model..
[84] A. Vulpetti,et al. Comparability of Mixed IC50 Data – A Statistical Analysis , 2013, PloS one.
[85] Andreas Bender,et al. From in silico target prediction to multi-target drug design: current databases, methods and applications. , 2011, Journal of proteomics.